Navigation Links
Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
Date:2/14/2013

ay not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-792-4438
Office: +972-2-566-0001       
Email: aviva@oramed.com 


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
2. Oramed Pharmaceuticals Announces Reverse Stock Split
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
5. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
6. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
7. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
8. Todays Research on Mylan and Watson Pharmaceuticals: One Drug Makers Sorrow is Another Ones Joy
9. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
10. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
11. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... (PRWEB) March 02, 2015 ... newly formed alliance with Shenzhen HANK Bioengineering Co., ... Ph.D. The alliance will establish a stem cells ... Province, China in September 2015. , Shenzhen HANK ... Zhang, an award-winning scientist, microbiologist and virologist, to ...
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine” or the “Company”) ... press release disseminated this morning by PR Web, and ... press release states that Immunovaccine has entered into a ... release did not originate from Immunovaccine and there is ... release. Please note that all official statements by ...
(Date:2/27/2015)... , Feb. 27, 2015 Research and Markets ... "Global Market Report of Trypsin" report to their ... (CAS 9002-07-7) aims at providing comprehensive data on Trypsin globally ... , North America , ... pays close attention to Trypsin This report focuses ...
(Date:2/27/2015)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... that it will be presenting at CALBIO 2015 at ... at 3pm PST. Patrick Lucy, chief business officer of ... state of the biosimilar industry landscape entitled The ... more information on CALBIO 2015 and The Evolving ...
Breaking Biology Technology:Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Immunovaccine Disclaims Hoax Press Release 2Global Market Report of Trypsin 2014-2018 2
... Ardea Biosciences, Inc. (Nasdaq: RDEA ) today ... offering of 2,750,000 shares of its common stock, offered ... share. The gross proceeds to Ardea from this offering ... underwriting discount and other estimated offering expenses payable by ...
... GAITHERSBURG, Md., Jan. 20, 2011 MedImmune,s Oncology group ... monoclonal antibody, broadly suppresses pathways that have been shown ... progression of many solid tumors. The study, published in ... (a journal of the American Association for Cancer Research), ...
... Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, ... company that creates, develops and tests innovative HIV/AIDS vaccines, is ... Community Awards.  Dr. Robinson will be honored at the GaBio ... Atlanta,s Fox Theater. Dr. Robinson is the developer ...
Cached Biology Technology:Ardea Biosciences Prices Public Offering of Common Stock 2Ardea Biosciences Prices Public Offering of Common Stock 3Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells 2Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells 3GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony 2GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony 3
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
(Date:2/5/2015)... , 5. Februar 2015 ... spezialisiertes Logistikunternehmen und hat eine neue Marketingkampagne ... Logistikfirma (Clinical Logistics Organization – CLO) der ... Kampagne lautet First , mit Schwerpunkt ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 Logo ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... April 6, 2010The Life Sciences Discovery Fund (LSDF) today ... support collaborative research initiatives spearheaded by three Washington state ... diverse approaches to enhance the diagnosis and treatment of ... by Stephen Friend of Sage Bionetworks, will use powerful ...
... the most prevalent diabetes-induced complications in men; current estimates suggest ... develop some degree of ED, and in many cases diabetics ... to standard drugs. Now, in a study appearing in ... Case Western Reserve University and Albert Einstein College of Medicine ...
... PHOENIX, Ariz. April 6, 2010 Scottsdale-based TGen ... Council (GPEC) this week at BayBio2010 in an effort ... one-day conference April 7 in San Francisco sponsored by ... 1,400 bioscience companies, more than any other single region ...
Cached Biology News:Washington State Life Sciences Discovery Fund awards health research program grants 2TGen Drug Development accompanies GPEC to BayBio2010 2
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... ChipReader systems are highly sensitive laser confocal ... These are advanced scanners that meet your ... background level, and optimizing the signal on ... end of the range for increased sensitivity. ...
... 96 assays on one plate. The new ... with 96 (7mm x 7mm) individual printing ... or screening analysis studies. Unlike other systems, ... eliminating the presence of contaminating adhesives. The ...
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
Biology Products: